These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30688008)

  • 1. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
    Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P;
    HIV Med; 2019 Mar; 20(3):202-213. PubMed ID: 30688008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
    Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
    Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
    de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
    HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy].
    Suzan-Monti M; Blanche J; Boyer S; Kouanfack C; Delaporte E; Bonono RC; Carrieri PM; Protopopescu C; Laurent C; Spire B;
    HIV Med; 2015 May; 16(5):307-18. PubMed ID: 25721267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.
    Landman R; de Truchis P; Assoumou L; Lambert S; Bellet J; Amat K; Lefebvre B; Allavena C; Katlama C; Yazdanpanah Y; Molina JM; Petrov-Sanchez V; Gibowski S; Alvarez JC; Leibowitch J; Capeau J; Fellahi S; Duracinsky M; Morand-Joubert L; Costagliola D; Alvarez JC; Girard PM;
    Lancet HIV; 2022 Feb; 9(2):e79-e90. PubMed ID: 35120640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
    Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM;
    HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
    Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
    Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].
    Michel L; Lions C; Winnock M; Lang JP; Loko MA; Rosenthal E; Marchou B; Valantin MA; Morlat P; Roux P; Sogni P; Spire B; Poizot-Martin I; Lacombe K; Lascoux-Combe C; Duvivier C; Neau D; Dabis F; Salmon-Ceron D; Carrieri MP;
    HIV Med; 2016 Nov; 17(10):758-765. PubMed ID: 27187027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic resistance profiles of HIV-2-treated patients in West Africa.
    Charpentier C; Eholié S; Anglaret X; Bertine M; Rouzioux C; Avettand-Fenoël V; Messou E; Minga A; Damond F; Plantier JC; Dabis F; Peytavin G; Brun-Vézinet F; Ekouevi DK;
    AIDS; 2014 May; 28(8):1161-9. PubMed ID: 24583671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study.
    Grabar S; Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; Pradier C; Salmon D; Simon A; Pourcher V; Spano JP; Poizot-Martin I; Costagliola D
    HIV Med; 2019 Mar; 20(3):222-229. PubMed ID: 30693646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
    Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
    Matheron S; Descamps D; Gallien S; Besseghir A; Sellier P; Blum L; Mortier E; Charpentier C; Tubiana R; Damond F; Peytavin G; Ponscarme D; Collin F; Brun-Vezinet F; Chene G;
    Clin Infect Dis; 2018 Sep; 67(8):1161-1167. PubMed ID: 29590335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018.
    Choufany M; Weiss L; Makinson A; Roul H; Livrozet JM; Pourcher V; Melica G; Rioux C; Viard JP; Marshall E; Grabar S; Costagliola D
    Clin Infect Dis; 2023 Apr; 76(8):1364-1371. PubMed ID: 36527700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.